Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics, Inc. is trading at $18.66, up 0.95% on the session. The 50 day average sits at $16.99 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 55.1, which reads as strong, and MACD is bearish crossover. Volume is below average.

The nearest support is around $17.52 with resistance near $19.26, so that band frames the current range. Average daily movement is roughly $1.00, or about 5.4% of the share price, which is what any stop placement has to allow for. The overall health score of 62 out of 100 combines a trend score of 75, momentum of 61 and a risk score of 42.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.